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RTKs, the second largest family of membrane receptors, transduce
biochemical signals upon lateral dimerization in the membrane plane
[1–3]. RTKs are single-pass membrane proteins, shown schematically
in Fig. 1. The N-terminal extracellular (EC) domains, usually several
hundred amino acids long, vary between families and contain
characteristic arrays of structural motifs. The single transmembrane
(TM) domain is followed by a 40 to 80 amino acid juxtamembrane
(JM) region and an ~250 amino acid kinase domain, homologous to
soluble tyrosine kinases [1,4,5].
RTK dimerization controls and ensures the close contact of the two
kinase domains in the dimer. Upon dimerization each kinase domain
catalyzes the phosphorylation of critical tyrosine residues in the
activation loop of the neighboring kinase [6]. This is followed by the
phosphorylation of additional tyrosine residues in the juxtamembrane
and catalytic domains, which serve as binding sites for docking proteins.
Upon recruitment and/or phosphorylation, these docking proteins
initiate intracellular signaling cascades that control vital cellular
processes [7–9].
RTKs, with a single exception (ErbB2), are ligand-binding proteins.
The ligands play intricate roles in the activation process [10], but are
not always essential for RTK dimerization and activation. Their
contribution to RTK activation is believed to be both thermodynamic(stabilizing RTK dimers) and structural (inducing RTK structural
changes which enhance RTK activity).
There are two requirements for successful activation of an RTK. The
ﬁrst requirement is the close approach of the two kinase domains in the
dimer. This is accomplished via dimerization. The dimerization
efﬁciency, and therefore the time the kinase domains spend in close
proximity of each other, are controlled by the dimerization constant.
Dimerization is modulated by ligand binding, and thus the proximity of
the kinase domains is also regulated by the ligand concentration and the
ligand binding constant. The second requirement for successful
activation of an RTK is that the structure of the kinase domain dimer
is suited for the transfer of a PO4 group from a bound ATPmolecule to a
particular tyrosine [9,11]. The phosphorylation-competent dimer
structure is established via speciﬁc receptor–receptor and receptor–
ligand interactions. Structural constraints in the extracellular and TM
domains, imposed upon dimerization and ligand binding, propagate
into the kinase domain and control RTK phosphorylation and activity.2. Physical–chemical models of RTK activation
We and others have proposed that RTK activation can be described
with physical–chemical models which account for dimerization,
ligand binding and phosphorylation [12–16]. Such models have
been shown to give an adequate description of RTK phosphorylation
data, despite their simplicity. Usually themodels do not take explicitly
into account all interactions that regulate RTK activation in cellular
membranes. Rather, all these events contribute to apparent constants
describing different steps in RTK activation. Here we provide a brief
overview of such models.
TK
TK TK
P P
P P
extracellular 
domain
monomer dimer
kinase domain
transmembrane 
domain
Fig. 1. A schematic of RTK architecture, showing the extracellular (EC) domain, the
transmembrane (TM) domain and the tyrosine kinase domain. The kinase domain is
linked to the TM domain via a 40–80 amino acid juxtamembrane (JM) domain. RTKs
transduce biochemical signals via lateral dimerization in the membrane. While the
monomers (left) are inactive, the dimers (right) are phosphorylated and active.
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Fig. 2. A schematic representation of the activation model given by Eq. (2). Two monomers
interact laterally to form dimers, both in the absence and presence of bound ligand
(dimerization constants K1 and K2, respectively). The ligand binds to both monomers
(association constant KM) and dimers (association constant KD). The receptors in the
unliganded and liganded dimeric states are phosphorylated, but the probabilities for
phosphorylationmaybedifferent (Φd for theunliganded state andΦD for the liganded state).
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Ligand-independent lateral dimerization, i.e., the lateral associa-
tion of two RTK monomers into an unliganded dimer, is the ﬁrst
critical step in RTK activation. It is controlled by the dimerization
constant K1 and is described by the following reaction scheme:
M + M↔
K1
d: ð1Þ
The dimerization constant K1 is deﬁned as K1=[d] / [M]2, with [M]
and [d] being the monomer and dimer concentrations, respectively.
The total receptor concentration is [T]=2[d]+[M]. The free energy of
dimerization is calculated as ΔG=−RT ln K1.
Unliganded RTK dimers can be phosphorylated or not. If the
unliganded dimers are phosphorylated, Eq. (1) accounts for the so-
called “basal or constitutive activation”. If the unliganded RTK dimers
are not phosphorylated (inactive), Eq. (1) accounts for the so-called
“pre-dimerization”. These two terms are vaguely deﬁned in biology,
but they have the same physical–chemical basis, i.e. Eq. (1).
2.2. Ligand binding
The next step in RTK activation is ligand binding, which is believed
to stabilize RTK dimers and likely alter their structure (discussed
below). The processes of dimerization and ligand binding are coupled,
and can be described by the following reaction scheme:
M + M↔
K1
d
þ L ↕ KM ↕ KD ↕ þ 2L
ML + ML↔
K2
D
; ð2Þ
where D denotes the liganded dimer (see also Fig. 2).
For the sake of simplicity, sometimes it is assumed that the ligand
binds preferentially to the unliganded dimers, rather than the
monomers [14]. In this case, Scheme (2) is reduced to the following
two coupled reactions:
M + M↔K1 d
d + L2↔
KD
D:
ð3Þ
In Scheme (3), the dimerization and the ligand binding constants
are deﬁned as K1=[d]/ [M]2 and KD=[D]/ [d][L]2, respectively. The
dimerization reaction is driven, in part, by ligand binding: Ligandbinding depletes the unliganded dimers by converting them to
liganded dimers, thus promoting the dimerization of the monomers.
All three Schemes (1) through (3), as well as more complex models
accounting for negative cooperativity in ligand binding, have been used
in the literature to rationalize experimental data and to gain insights
into how dimerization and ligand binding regulate RTK activation [12–
16]. While these models are simple and do not capture the full
complexity of RTK signaling, they are very useful in comparative studies,
such as studies of the effects of sequence variations and pathogenic
mutations on different steps in RTK activation, as discussed below.
2.3. Phosphorylation
In the dimer, the two receptors autophosphorylate each other,
with each kinase domain acting as an enzyme which facilitates the
transfer of a phosphate group to the neighboring kinase. One way to
account for the efﬁciency of phosphorylation is to deﬁne receptor
phosphorylation probabilities, Φd and ΦD, within the unliganded and
liganded dimers, respectively [17]. The concentration of phosphory-
lated receptors is then calculated according to:
P½  = 2Φd d½  + 2ΦD D½ : ð4Þ
Note that Φd=0 corresponds to inactive unliganded dimers and
describes predimerization, while Φd≠0 describes active unliganded
dimers and accounts for basal or constitutive activation.
3. Experimental characterization of RTKs
3.1. Measurements of RTK dimerization
To characterize RTK dimerization in the context of Eq. (1), one
needs to measure directly two of the following three parameters over
a range of RTK concentrations: (i) concentrations of RTK dimers,
(ii) concentrations of RTK monomers, and (iii) total RTK concentra-
tions. Quantitative measurements of these concentrations, and thus
calculations of dimerization constants for full-length RTKs are a
challenge. However, some widely used biochemical methods allow us
to estimate and compare dimerization propensities.
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the cells are incubated with a cross-linker, lysed, and analyzed using
Western blotting. Since only RTKs in very close proximity can be
cross-linked, the presence of cross-linked bands on Western blots
suggests that dimers exist on the cell surface. Furthermore, higher
cross-linking correlates with higher dimerization. While the method
is useful and well established, it should be kept in mind that the cross-
linker is non-speciﬁc, such that it cross-links all proteins in close
proximity. As a result, gels of cross-linked proteins are usually
smeared, and very difﬁcult to accurately quantify. Furthermore, a
limitation of this experimental approach is that the cross-linking
propensities depend not only on close proximity, but also on
structure. Thus, a structural change can alter the probability for RTK
cross-linking, despite the fact that RTK dimerization is not affected.
Another method used in the literature for assessment of RTK
dimerization is immunoprecipitation, followed by SDS-PAGE [22].
Disulﬁde-linked RTK dimers have been observed using this technique
under oxidizing conditions without cross-linking. In this case,
however, the assay reports on interactions occurring within the
immunoprecipitates. Thesemight be different from interactions in the
native plasma membrane, which imposes structural constraints on
RTK dimers. In particular, the presence of unpaired cysteines in the
receptors may lead to the formation of non-native disulﬁde bonds in
the immunoprecipitate and give a false positive for dimer formation.
A powerful method used to study dimerization is Förster
resonance energy transfer (FRET) [23–27]. FRET involves the non-
radiative energy transfer from a ﬂuorescent donor to a ﬂuorescent
acceptor [28–32], and is manifested in a decrease in donor
ﬂuorescence and an increase in acceptor ﬂuorescence [30–32] upon
dimerization. The efﬁciency of energy transfer E is inversely
proportional to the sixth power of the distance, r, between the
donor and acceptor. The transfer efﬁciency E is a function of r and Ro,
the characteristic Förster radius for the donor and acceptor pair:
E ¼ 1=½1þ ðr=R0Þ6: ð5Þ+
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Fig. 3. Overview of RTK dimerization measurements in plasma membrane-derived vesicles.
vesiculated using established protocols. The vesicles are imaged in a confocal microscope, acq
in [53–55], is used to determine the donor and acceptor concentration, and the FRET efﬁci
monomers and dimers in each vesicle, the dimerization constant K1 and the free energy ofTypical donor/acceptor pairs, such as the widely used ﬂuorescent
proteins, have Ro of 50–60 Å. Thus, if the two ﬂuorophores are closer
than 50 Å in a dimer, FRET will occur.
FRET can be measured in the native cellular environment. In these
experiments the genes encoding the RTKs are modiﬁed by attaching
sequences encoding ﬂuorescent proteins, usually at RTK's C-termini.
While most in-cell FRET experiments measure the sensitized acceptor
emission, sophisticated FRET techniques have been developed to assess
donor quenching [33–38]. Whenmeasuring interactions in membranes
using FRET, however, special care needs to be exercised since FRET
occurs even if there are no speciﬁc interactions, due to random co-
localization of donors and acceptors [39–42]. Furthermore, challenges in
data interpretation arise because the cellular environment is highly
heterogeneous, and supramolecular organizations in clusters/domains
introduce additional heterogeneities affecting the measured FRET
efﬁciency and complicating data analysis.
To overcome the above challenges, we have established plasma
membrane-derived vesicles [43–48] as a model system for studies of
RTK interactions in mammalian membranes via FRET (Fig. 3). Plasma
membrane-derived vesicles are produced using either a mechanical
method, by breaking the plasma membrane, or using chemical
methods, by disrupting the cytoskeleton in a direct or indirect
(apoptotic) way [49–52]. Plasma membrane-derived vesicles are a
simpliﬁed model of the cell membrane because there is no
cytoskeleton and no TM potential [43]. Yet, plasma membrane-
derived vesicles possess complex features that are characteristic of
native cellular membranes [43–48]. Their lipid composition is similar
to the one in the native membrane [43], and they maintain the plasma
membrane asymmetry [44–46]. The membranes of the vesicles
contain various membrane proteins and mimic the natural crowded
membrane environment.
We have demonstrated that quantitative measurements of RTK
dimerization in single vesicles are feasible with the QI-FRET method
[53]. The QI-FRET method, discussed in [53–55], yields the unknown
donor and acceptor concentrations, and the FRET efﬁciency (i.e. the
three parameters that are sufﬁcient to calculate free energies ofTK
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Cells are transfected with genes encoding RTKs fused to ﬂuorescent proteins, and then
uiring donor, acceptor and FRET images for each vesicle. The QI-FRETmethod, described
ency in each vesicle. This information is then used to determine the concentrations of
dimerization.
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fection, expression levels vary from cell to cell, and vesicles with a
wide range of receptor concentrations (i.e., number of receptors per
unit membrane area) can be produced in a single transfection
experiment. Thus, a wide protein concentration range is sampled,
and the dimerization energetics are measured for different receptor
concentrations, to obtain dimerization curves.
Using this methodology, we have measured the energetics of
FGFR3 TM domain dimerization in the plasmamembrane of CHO cells,
as well as the dimerization energetics of a construct containing both
FGFR3 EC and TM domains [55]. The two dimerization free energies
were determined as ΔG(TM)=−RTlnKD(TM)=−4.2±0.2 kcal/mol
and ΔG(EC+TM)=−3.3±0.1 kcal/mol, respectively.
3.2. Characterization of ligand binding
The binding of ligands to full-length receptors on the surface of
living cells is usually measured by quantifying bound radiolabeled or
ﬂuorescently-labeled ligands. Binding of ligands to isolated RTK
extracellular domains can be characterized using isothermal titration
calorimetry, ultracentrifugation, and surface plasmon resonance
(SPR), as described below.
The most popular method to probe interactions between ligands
and cell surface receptors involves quantiﬁcation of bound radiola-
beled ligands. In these experiments, cells are incubated with
radiolabeled ligands either on ice or at ambient temperature
(to minimize receptor cell uptake). The free ligands are removed, a
process which usually requires extensive washing with concentrated
salt solutions. Then the cells are lysed and the radioactivity of the
receptor-bound ligands is measured. Binding curves can be generated
by performing the measurements at different concentrations of
ligands. This method has been used to investigate EGF binding afﬁnity
to EGFR [56,57], and the interactions between FGF1 and FGF receptors
[58,59]. Furthermore, the bound ligands can be crosslinked to the
receptors, such that the ligand–receptor complexes remain intact
when the cell lysates are run on SDS-PAGE gels [59].
Fluorescence-based methods are an alternative to the traditional
radiolabeling approach since the ﬂuorescence intensity of the bound
ligand is easily measured in a standard spectroﬂuorometer [60]. The
receptor–ligand interactions on the cell surface can be further
investigated using single molecule ﬂuorescence techniques. These
techniques have allowed the visualization of single bound EGF
molecules, and have provided insight into the binding kinetics
[61,62]. Fluorescence correlation spectroscopy (FCS) with single-
molecule sensitivity is also used to quantitatively analyze ligand–
receptor interaction on the surface of living cells. This technique has
yielded the EGF-EGFR dissociation constant, via the analysis of
ﬂuorescence intensity ﬂuctuations in a small confocal volume [63].
Ligand binding to the isolated RTK extracellular domains has also
been characterized. For instance, isothermal titration calorimetry,
ultracentrifugation and molecular modeling [64] have been used to
characterize the energetics and kinetics of the interactions between
FGF1, FGFR1 extracellular domains, and heparan sulfate in solution.
Alternatively, the ligands or the extracellular domains can be attached
to a surface, and the interactions can be analyzed using SPR. Such
studies have provided valuable insight into the speciﬁcity of FGF–
FGFR interactions [65–67].
3.3. RTK phosphorylation measurements
Methods to measure RTK phosphorylation are well established.
Phosphorylation levels are monitored by either [1] in-vitro kinase
assays, [2] quantiﬁcation of bound antibodies that speciﬁcally
recognize phosphorylated tyrosines, or [3] mass spectrometry
identifying attached phosphate groups.In vitro kinase assays often utilize radioactive phosphorous. In these
assays cell lysates containing RTKs of interest are incubated with kinase
bufferwithATPcontaining radiolabeled phosphates. The radioactivityof
the receptors is quantiﬁed upon the transfer of the radioactive
phosphate groups to the kinase domains [68]. Alternatively, RTK
phosphorylation can be quantiﬁed without the use of radioactivity by
coupling it with the oxidation of NADH, and then following NADH
oxidation using spectrophotometric assays [69].
RTK phosphorylation can be measured with the use of antibodies
that recognize phosphorylated tyrosines. The amounts of such bound
antibodies can be determined using traditional Western blots, ELISA,
or in-cell Western blot techniques. These experiments usually involve
secondary antibodies which interact with the primary ones, and are
conjugated to reporter moieties, detectable using either chemilumi-
nescence or ﬂuorescence. Two different types of primary antibodies
can be used: (1) antibodies recognizing all phospho-tyrosines, such as
the 4G10 anti-phosphotyrosine antibody, capable of detecting over 30
tyrosine kinases, including ErbB2 [70], PDGFR [71], and FGFR3 [72],
and (2) antibodies generated against speciﬁc phosphorylated sites,
recognizing a particular phosphotyrosine together with the sequence
around it [14,15]. The latter are useful because RTK kinase domains
normally contain more than one tyrosine residue, and the phosphoryla-
tion of the different tyrosines occurs sequentially [73,74].
In recent years, mass-spectrometry has become popular in studies
of RTK phosphorylation [75–77], and we foresee that its usage will
continue to increase. In this method, the phosphorylated RTKs are
puriﬁed via immunoprecipitation and are digested with trypsin. The
products of digestion (peptides) are analyzed by either Matrix-
associated laser desorption ionization time-of-ﬂightMass Spectrometry
(MALDI-TOF MS) or Electrospray Ionization Mass Spectrometry (ESI-
MS) [78]. By comparing the masses of the peptides with a “theoretical
digest”, the presence of phosphate groups can be detected. This method
has been used to identify the phosphorylation sites of PDGFR [79] and
EGFR [80].
4. Structural requirements for RTK activation
As discussed above, RTK activation requires precise orientation
and positioning of the catalytic domains with respect to each other,
such that the phosphate group can be successfully transferred from
ATP to the neighboring receptor. For EGFR, this entails the formation
of an asymmetric kinase dimer in which the C-lobe of one kinase
contacts the N-lobe of the second kinase and positions the activation
loop of the second kinase to catalyze phosphate group transfer [9]. The
existence of asymmetric dimers has been proposed for FGF receptors,
too [81]. It is not yet clear, however, whether such asymmetric dimers
form for all RTKs, and whether the two kinases alternate over time
and act both as catalysts and substrates.
The order of the phosphorylation of the different tyrosines is also
controlled by the structure of the kinase domain. For instance, the
order of tyrosine phosphorylation in FGFR1 kinase domain is strict,
and kinetically controlled. It is limited by the rate of transfer of the
phosphate group from ATP to the tyrosines [73], and strongly
inﬂuenced by the kinase tertiary structure [73,74].
The structure and orientation of the kinase domains, on the other
hand, are controlled by speciﬁc interactions between the TM domains,
as well as interactions between the EC domains and the ligands, as
discussed below.
4.1. Structural constraints imposed by the TM domain dimers
The TM domain structure has been shown to control the
orientation of the kinase domains in the dimer, such that successful
phosphorylation can occur [11]. In particular, rotation of the dimer
interface has been shown to induce periodic oscillations in kinase
activity [11]. Therefore, the structure of the TM domain dimer is an
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ago, a ﬁve-residue sequence motif (the so-called P0–P4 motif) was
proposed to mediate dimerization of RTK TM domains [82]. The
characteristics of the P0–P4 motif are: P0 exhibits a small side chain,
such as Gly, Ala, Ser, Thr, or Pro; P3 requires an aliphatic side chain, i.e.
Ala, Val, Leu, or Ile; and P4 must be a Gly or Ala residue. The P0–P4
motif is similar to the GxxxGmotif [83,84], shown to be important for
Glycophorin A (GpA) dimerization. Later, the TM sequences of ErbB1,
ErbB2, and ErbB4 were noticed to have at least two such GxxxG-like
motifs [85], and the different GxxxG-like motifs were proposed to
mediate either homo or hetero-dimerization [90,91]. Alternatively,
based on calculations of dimerization free energies of alternate ErbB2
TM domain structures, it was proposed that some RTK TM domains
may form two alternative homodimer structures utilizing different
GxxxG-like motifs, a phosphorylation-competent structure and an
inactive structure [17,86,87].
The solved crystal structure of the ErbB2 TM dimer provided
demonstration that dimerization occurs via the N terminal GxxxG
dimerization motif, while the C terminal motif does not participate in
the dimer interface [88]. A similar GxxxG-like motif is involved in the
dimerization of a different RTK, EphA1 [89]. Yet, the GxxxG motif is
not required for the dimerization of all RTKs. For instance, the dimer
interfaces of ErbB3, EphA2, PDGFR and FGFR3 TM domains do not
involve GxxxG-like motifs, despite the fact that their sequences
contain several such motifs [92–96].4.2. Structures of ligand-bound extracellular domain dimers
The solved crystal structures of isolated RTK extracellular domains
reveal tight contacts between the two EC domains, and between the
EC domains and ligands. The contacts between EGFR EC domains are
mediated via a “dimerization arm”, exposed only upon ligand binding
[97–99]. A recent crystal structure of an EGFR drosophila variant
reveals very strong interactions between the two EC domains when
only one ligand is bound to dimer [100].
In the FGF2 structure bound to FGFR1, there are many contacts
between each ligand and the two receptors, as well as direct receptor–
receptor interactions [101–103]. The structure further reveals a
positively-charged lysine-rich “canyon” where heparin oligosaccha-
rides bind, interacting with both the extracellular domains and the
ligands, further stabilizing the dimer. Growth factors for families other
than EGFRs and FGFRs, (such as KIT and VEGFR), are covalently linked
homodimers that bring the extracellular domains together, which
promotes additional interactions between the extracellular domains
[104,105].4.3. Structural changes mediated by ligands
The ligands of some receptors are believed to not only introduce a
structural change in the extracellular domain, but also affect the
conformation of the kinase domain, thus increasing RTK activation.
For instance, the EGFR unliganded dimer is believed to be inactive
because the asymmetric kinase dimer, required for activity [9], cannot
form in the absence of ligand. Ligand binding likely induces a rotation
in the EGFR dimer and ensures correct positioning of the two kinase
domains for phosphorylation [106]. The dimeric ligand of KIT,
believed to stabilize the dimer by cross-linking the two monomers
[104], also induces a structural change which enables receptor–
receptor interactions. These interactions are weak as compared to
ligand-mediated dimer stabilization and thus they do not drive
dimerization by themselves. However, these interactions deﬁne the
relative orientations of the two receptors, which likely helps to
position the kinase domains in the correct orientation for productive
phosphorylation.5. RTK involvement in human disease
5.1. Pathogenic mutations in RTKs
Since RTKs play a key role in the regulation of cellular processes
that are critical for cell growth, differentiation, and motility, defects in
their activation lead to human pathologies. There are many
pathogenic single amino acid mutations in RTKs that are usually
(but not always) gain-of-function mutations. Because RTK activity is
determined by RTK phosphorylation, studies of pathogenic mutations
invariably involve experiments which assess the effect of these
mutations on phosphorylation. The simplest way to address this
question is to compare wild-type and mutant expression and
phosphorylation, side-by-side on Western blots. If the expression of
the wild-type and the mutant is the same, then the phosphorylation
levels can be directly compared. Such direct comparisons have shed
light on the molecular basis behind many pathologies [68,107–109].
Direct comparisons of phosphorylation onWestern blots have also
shed light on how different mutations in a particular RTK can give rise
to different phenotypes. One such study compared the phosphoryla-
tion of two FGFR3 mutants, linked to achondroplasia (ACH) and
thanatophoric dysplasia (TD) [109]. ACH, the most common form of
human dwarﬁsm [110,111], is a relatively mild phenotype character-
ized by short stature [112]. On the other hand, TD is muchmore severe
and always lethal in the neonatal period, characterized by severe
shortening of the limbs, macrocephaly, and a narrow thorax with
small ribs [112]. The phosphorylation of the R248C and K650E
mutants, associated with TD, has been shown to be higher than the
phosphorylation of the G380Rmutant linked to ACH [109]. Thus, there
is a link between higher phosphorylation and more severe
phenotypes.
The effect of pathogenic mutationsmay be diverse, andmay include
processing defects, such as impeded trafﬁcking and defective down-
regulation [111,113,114]. Inmany cases, the expression of themutant is
different from the expression of the wild-type in cell lines that are
widelyused inbiomedical research. If the expressionsaredifferent, side-
by-side comparison of phosphorylation on Western blots is not very
informative. To be able to carry out such a comparison, we need to
obtain an absolute measure of the phosphorylation at a particular
expression level. We have shown that measurements of “phosphory-
lated fractions” as a function of expression levels can serve this purpose
[15,16]. In these experiments we treat RTKs with their ligands and we
measure phosphorylation over a very wide range of ligand concentra-
tions, including very high ligand concentrations [14]: At high ligand
concentration all receptors that are exposed to ligand and capable of
binding ligand are driven to their liganded dimeric state. At these levels,
phosphorylation is saturated and is not further increased when more
ligand is added, providing a measure of the maximum possible
phosphorylation [14,16]. Phosphorylated fractions are then determined
as the ratio of measured phosphorylation at a particular ligand
concentration over the maximum possible phosphorylation [14,16],
and are independent of the speciﬁc conditions used in theWestern blot
experiments. Using this technique, we have compared the phosphoryla-
tion of wild-type FGFR3 and the pathogenic A391E mutant linked to
Crouzon syndrome in the absence of ligand, demonstrating an increase in
FGFR3 phosphorylation due to the A391E mutation, despite the fact that
the expression of the wild-type and the mutant was different [15].5.2. Physical–chemical causes for RTK-linked pathologies
5.2.1. Altered dimerization
Some pathogenic mutations stabilize RTK dimers, by promoting
more intimate contacts between the two mutant receptors in the
dimer (see Table 1 for examples). As a result, the dimerization
propensity (i.e. K1 in Schemes (1) through (3)) increases. The
Table 1
A list of characterized pathogenic RTK mutations, and the underlying physical–chemical cause for the pathologies. All RTKs are human, unless stated otherwise.
RTK Mutations Location Phenotype Cause for pathology
FGFR1 P252R Extracellular domain Pfeiffer syndrome Increased ligand binding [145].
FGFR1 Y372C Extracellular domain Osteoglophonic dysplasia Increased dimerization [103].
FGFR2 S252W, P253R Extracellular domain Apert syndrome Increased ligand binding [146].
FGFR2 D321A Extracellular domain Pfeiffer syndrome Increased ligand binding [146].
FGFR2 C278F, C342Y, Extracellular domain Crouzon syndrome
and Pfeiffer syndrome
Increased dimerization [22].
FGFR2 W290G, S354C, Y340H C342Y Extracellular domain Crouzon syndrome Increased dimerization [22,147].
FGFR2 T341P Extracellular domain Pfeiffer syndrome Increased dimerization [22].
FGFR3 R248C, S249C Extracellular domain Thanatophoric dysplasia type I Increased dimerization [148].
FGFR3 P250R Extracellular domain Muenke syndrome Increased ligand binding [145].
FGFR3 G370C, S371C, Y373C Transmembrane domain Thanatophoric dysplasia type I Increased dimerization [148,149].
FGFR3 G375C Transmembrane domain Achondroplasia Increased dimerization [149].
FGFR3 G380R Transmembrane domain Achondroplasia Structural change [14].
FGFR3 A391E Transmembrane domain Crouzon syndrome with
acanthosis nigricans
Increased dimerization [15].
FGFR3 K650E Kinase domain Thanatophoric dysplasia type 2 Structural change in the kinase domain [150].
FGFR4 Y367C Extracellular domain Breast cancer Increased dimerization [151].
EGFR EGFRvIII. 6–273 deletion Extracellular domain Glioblastoma Structural change [152].
EGFR T263P, A289V, P596L, G598V Extracellular Domain Glioblastoma Increased dimerization [153].
EGFR G719S Kinase domain Non-small-cell lung carcinoma Structural change in the kinase domain [154].
EGFR L858R Kinase domain Non-small-cell lung carcinoma Structural change in the kinase domain
and increased ligand binding [9,155].
EGFR 752–759 deletion and L861Q Kinase domain Non-small-cell lung carcinoma Structural change in the kinase domain [155].
EGFR 959–1030 deletion C-terminal tail Glioblastoma Structural change in the kinase domain [156].
ErbB2 (Rat) V664E Transmembrane domain Oncogenic in rat Increased dimerization [16].
KIT 417–419 deletion and T417I Extracellular domain Acute myeloid leukemia (AML) Increased dimerization [157].
KIT V559D Juxtamembrane domain Gastrointestinal stromal tumor Structural change in the
juxtamembrane domain [158,159].
KIT V560G Juxtamembrane domain Mastocytosis Increased dimerization [158,160].
KIT (Murine) KΔ27.
547–555 deletion and D560K
Juxtamembrane domain Mastocytoma Increased dimerization [161].
KIT D816V Kinase domain Mastocytosis Structural change and increased
dimerization (under debate) [162–164].
PDGFRA V561D Juxtamembrane domain Gastrointestinal stromal tumors Increased dimerization [165].
PDGFRA D842V Kinase domain Gastrointestinal stromal tumors Increased dimerization [165].
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toward the active dimeric state, increasing the over-all RTK activity.
To test for enhanced dimerization due to pathogenic mutations,
one needs to use a direct dimerization assay such as the one shown in
Fig. 3. In our lab we have used this assay to investigate the effect of
two pathogenic FGFR3mutations, A391E and G380R.While the A391E
mutation linked to Crouzon syndrome increases FGFR3 dimerization,
the G380R mutation linked to ACH does not (paper in preparation).
This behavior correlates with the mutation-induced stabilization of
the isolated FGFR3 TM domain dimers in lipid bilayers [95,115].
Receptor overactivation due to increased dimerization may occur
even for wild-type receptors if the receptor is overexpressed. This
mechanism can be understood using Eq. (1). As the total concentra-
tion of receptors increases, the equilibrium is shifted toward the
active dimeric state.
5.2.2. Altered ligand binding
There are pathogenic RTK mutations that increase ligand binding
(KM or KD in Schemes (2) and (3)). Increased ligand binding leads to
dimer overstabilization and enhanced phosphorylation. Techniques
that assess ligand binding strengths are well established (and
reviewed above), and can be used to compare the binding of ligands
to wild-type and mutant receptors. Such direct binding measure-
ments, for example, have demonstrated aberrant ligand binding to
FGFR mutants implicated in human growth disorders (Table 1).
5.2.3. Structural changes in the kinase domains
Some pathogenic mutations induce structural changes in RTK
dimers (Table 1), affecting the receptor phosphorylation proba-bilities, Φd and ΦD in Eq. (4). In this case the number of dimers is not
increased, but the mutant dimers are more active than the wild-type
dimers, leading to an over-all increase in activity. Presumably, this
occurs because it is easier to phosphorylate critical tyrosines in the
mutant dimers, as compared to the wild-type dimers [116]. Such
structural changes may originate outside the kinase domain and
propagate throughout the whole structure [106].
High resolution structures of full-length RTKs are not available yet,
due to experimental challenges in the expression of full-length RTKs
in large quantities [117]. Since the determination of full-length RTK
dimer structures is challenging, studies of the effect of pathogenic
mutations on dimerization, ligand binding, and phosphorylation may
help us deduce possible structural changes in mutant RTK dimers. For
example, the G380R mutation increases FGFR3 phosphorylation, but
does not increase FGFR3 cross-linking or ligand binding [14]. We have
interpreted these ﬁndings as an indication for a structural change. In
support of this view, a molecular model of the FGFR3 TM dimer
structure suggests that the mutation induces a rotation in the TM
dimer interface [14]. On the other hand, the changes in the
phosphorylation and dimerization propensities due to the A391E
mutation linked to Crouzon syndrome are very similar, suggesting
that the mutation likely affects FGFR3 dimerization propensity, but
does not induce a signiﬁcant structural change [15,95].5.2.4. Multiple effects
Some mutations may affect multiple steps in the RTK activation
process. An approach to understand the effect of pathogenic mutations
on dimerization, ligand binding, or receptor phosphorylation probabil-
ities is to model RTK activation using physical–chemical models such as
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experimental data, we can determine if a mutation affects dimerization
(i.e. K1 or K2), ligand binding (KL or KM) or phosphorylation (Φd orΦD).
In one example, Pike and colleagues measured EGF binding to EGFR
while varying both the receptor and ligand concentrations [12,13]. By
ﬁtting amodel similar to theone given by Eq. (2) to their data, theywere
able to determine that an engineered mutation in the extracellular
domain of EGFR, Y246D, decreases ligand binding, while an L680N
mutation in the kinase domain of EGFR affects both EGFR dimerization
and ligand binding. While quantitative measurements of RTK phos-
phorylation, dimerization, and ligand bindingmay be very tedious, their
pay-off could be signiﬁcant: The understanding of how a mutation
affects RTK activity is the ﬁrst step toward the development of new
therapeutic strategies with high efﬁciencies and low toxicities.
6. Thermodynamics of RTK dimerization
In this last section, we overview recent ﬁndings that pertain to the
thermodynamics of RTK dimerization as a regulator of RTK activity.
6.1. Contributions of RTK domains to RTK dimerization thermodynamics
6.1.1. Transmembrane (TM) domains
Biophysical studies of the isolated RTK TM domains have provided
a direct assessment of the contribution of RTK TM domains to RTK
dimerization energetics. All isolated RTK TM domains have been
shown to dimerize in bacterial membranes, with the dimerization
strength varying between families and within the families [118].
Quantitative studies of dimerization in lipid vesicles have shown that
the contribution of FGFR3, ErbB1 and EphA TM domains to
dimerization is about −3 kcal/mol [119–123]. FGFR3 TM domains
have been further shown to drive ligand-independent dimerization in
plasma membrane-derived vesicles in the absence of ligand in the
presence of the EC domain [54]. As a result, sequence changes in RTK
TM domains affect RTK dimerization at zero ligand and at low ligand
concentrations [124,125]. At high ligand concentrations, however, the
contribution of the TM domains to dimerization is overshadowed by
the large contributions of the EC domains and ligands. Thus, TM
domain sequence alterations do not affect RTK dimerization and
activation signiﬁcantly at high ligand concentrations [124,126].
6.1.2. Extracellular (EC) domains and ligands
Based on the solved dimeric structures of isolated extracellular
domains bound to ligand, it can be expected that ligand binding
stabilizes RTK dimers. Indeed, in all such structures, despite a great
deal of structural diversity, we see tight contacts between the two EC
domains in the dimer and between the EC domains and ligands
(discussed above). However, this view was questioned recently for
EGFR in a study of EGFR diffusion, as ligand binding per se did not
appear to stabilize EGFR dimers [127].
The crystal structure of the EC domain dimer of a drosophila EGFR
variant shows very intimate contacts between the two EC domains
when only one ligand is bound [100]. The comparison of this structure
to the symmetric human EGFR structure in the presence of two bound
ligands [97,128] suggests that the binding of the ﬁrst ligand is strongly
stabilizing, while the second ligand binding event decreases dimer
stability. This new ﬁnding suggests that the mechanism of ligand-
induced RTK dimer stabilization is unexpectedly complex.
In the absence of ligand, the EC domains have been shown to
inhibit dimerization. The contribution of FGFR3 extracellular domain
to dimerization has been demonstrated to be inhibitory in plasma
membrane derived vesicles, and its magnitude has been measured as
ΔΔG=0.9±0.2 kcal/mol [55]. Thus, the EC domains play a dual
thermodynamic role in RTK dimerization, inhibiting dimerization in
the absence of ligand and stabilizing the dimers in the presence of
ligand.6.1.3. Catalytic domains
The cross-phosphorylation of the kinase domains implies the
occurrence of contacts between them [7–9]. These contacts are likely
to be stabilizing. Yet, the contribution of the kinase domains to RTK
dimerization energetics has not beenmeasured experimentally thus far.
It is possible that this contribution depends on the phosphorylation
state. The JM domain, a 40 to 80 amino acid-long sequence between the
TMdomain and the catalytic domainmay be further contributing to the
interactions, by stabilizing the active conformation of the kinase
domain, and mediating direct receptor–receptor contacts [129,130].
6.2. RTK heterodimerization
Heterodimerization between RTKs is a means of signal ampliﬁca-
tion, as well as diversiﬁcation [131]. RTK heterodimers have been
shown to enhance receptor activation and downstream signaling, as
compared to homodimers [131–133]. For instance, the ErbB2/ErbB3
heterodimer is believed to be the most biologically active and the
most pro-tumorigenic of all ErbB homo and heterodimers [134,135].
Multiple studies, focusing primarily on the ErbB family of receptors,
have demonstrated the importance of heterodimerization in normal
function and in disease [136–140]. For example, ErbB1/ErbB2,
ErbB1/ErbB4, and ErbB2/ErbB4 heterodimers have been shown to
play a role in cell transformation. Furthermore, ErbB3 is over-
expressed in many tumors that overexpress ErbB2, including breast,
bladder, and melanomas [131,140]. Tumors that overexpress ErbB2
also exhibit elevated ErbB3 phosphorylation levels [134]. Yet, our
understanding of RTK heterodimerization is only rudimentary, in part
due to a paucity of methods that provide quantitative information
about RTK heterodimerization. Thus far, heterodimerization between
the isolated ErbB TM domains has been studied in detergents using
FRET [141] and in bacterial membranes using the genetic assay
GALLEX [91]. These studies have suggested that ErbB TM domains
form both homodimers and heterodimers with various stabilities.
Germ-line mutations in FGFR receptors cause heterozygous
disorders of bone development [112,142,143], as the homozygous
conditions are lethal. Thus both wild-type and mutant receptors are
co-expressed in cells, and questions arise if wild-type/mutant
heterodimers form and what their activity is. The interpretation of
heterodimerization studies, however, is very challenging because
three different dimeric species usually exist: (1) wild-type homo-
dimers, (2) mutant homodimers, and (3) wild-type/mutant hetero-
dimers. These dimers are indistinguishable in many biochemical
experiments, as wild-type and mutants are reactive to the same
antibodies. Oneway to characterize heterodimerization is to use FRET,
with the wild-type labeled with a donor and the mutant with an
acceptor (or vice versa). In this case, the FRET efﬁciency can be
measured easily. However, the heterodimerization propensities are
challenging to quantify because RTKs also form homodimers. Fig. 4A
illustrates the challenge in such measurements, arising due to
coupling between the homo and heterodimerization equilibria. The
association constant of heterodimerization, Kxy, depends on the
monomer concentrations of the two receptors, [X] and [Y]. The
same monomer concentrations, however, appear in the equations
describing the homodimerization constants Kx and Ky. Thus, homo-
dimer stabilities need to be determined ﬁrst, and then these are used
to determine heterodimer stabilities [141,144].
We have demonstrated the feasibility of this approach by
determining the propensity for heterodimer formation between the
wild-type FGFR3 TM domain and its A391E mutant [144], linked to
Crouzon syndrome. The free energy of heterodimerization was
determined as −3.37±0.25 kcal/mol [144]. Comparison of this
value to the homodimerization free energies for the wild-type,
−2.8±0.2 kcal/mol, and the mutant, −4.1±0.2 kcal/mol, demon-
strates that the heterodimer stability is the average of the two
homodimer stabilities [144].
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Fig. 4. Characterization of RTK heterodimerization. (A). FRET measurements of
heterodimerization propensities between RTKs. One RTK is labeled with a donor, and
the second RTK is labeled with the acceptor, such that the FRET efﬁciency can be
measured. However, the calculation of the heterodimerization free energy is not trivial
because the homo and heterodimerization equilibria are coupled. A detailed protocol
for characterization of heterodimerization energetics using FRET is given in [144].
(B). An overview of an assay for RTK heterodimerization that does not require
modiﬁcation with ﬂuorescent proteins. A stable cell line expressing full-length RTKs
(green) is transiently transfected with a truncated version of a second RTK (blue)
lacking the intracellular domain. The inactive full-length/truncated heterodimers
deplete the pool of full-length receptors capable of forming homodimers and reduce
their phosphorylation. The decrease in the phosphorylation of the full-length receptors
is measured experimentally. This decrease is a reporter of heterodimerization strength
between the RTKs that are stably and transiently expressed. Detailed description of the
assay is given in [124].
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dimers is to design an RTK construct that lacks the kinase domain, and
then monitor the formation of heterodimers between this construct
and full length RTKs (Fig. 4B). The full-length/truncated heterodimers
are inactive. They deplete the pool of full-length receptors capable of
forming homodimers and ultimately reduce the concentration of
active homodimers. Thus, the presence of the truncated receptors
leads to a decrease in the phosphorylation of the full-length receptors
if the full-length and the truncated receptors dimerize. This decrease
in phosphorylation can be measured experimentally. Because thecontributions of the kinase and the juxtamembrane domains to RTK
dimerization may be non-negligible and different for different RTKs,
this approach can only be used to assess the effect of pathogenic
mutations in the extracellular and TM domains on heterodimerization
[124]. This is because the contributions of the intracellular domains
are expected to be the same for the wild-type and mutant
homodimers and heterodimers, but not for heterodimers of different
RTKs. This approach has revealed that heterodimers of wild-type
FGFR3 and the G380R mutant linked to ACH form with lower
probability than wild-type FGFR3 homodimers in cellular membranes
[124].
7. Final remark
As discussed in this review, quantitative biophysical frameworks,
as well as sophisticated biochemical and biophysical experimental
methods are now being used to unravel the physical–chemical
principles behind RTK activation and their involvement in disease.
The recent progress in the ﬁeld has been impressive, and we look
forward to future studies that will further deepen our understanding
of RTK structure and function and pave the way for the development
of novel targeted therapies for RTK-linked pathologies.
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